Skip to main content
. Author manuscript; available in PMC: 2017 Jan 16.
Published in final edited form as: J Mol Biol. 2007 May 10;371(1):269–282. doi: 10.1016/j.jmb.2007.05.012

Figure 2.

Figure 2

CD39 palmitoylation is not required for its incorporation in HIV-1. (a) Isogenic viral particles were produced in 293T cells by cotransfection of pNL4-3 and an expression vector coding for either wild type or N-truncated CD39 (CD39Δ1-37). A similar amount of each viral preparation was subjected to a viral capture assay using magnetic beads coated with an anti-CD39 antibody or an isotype-matched irrelevant control antibody (IgG1). The amount of captured virus was estimated by measuring the p24 content. The results shown are the mean ± standard deviation of triplicate samples and are representative of two separate experiments. (b) Cells were transfected with wild-type CD39 or CD39Δ1-37 vector and stained with FITC-conjugated cholera toxin B (CTB) and anti-CD39 to visualize lipid rafts and CD39, respectively. (c) Cells were cotransfected with pNL4-3 and wild-type CD39 or CD39Δ1-37 vector before staining with human anti-HIV-1 and anti-CD39. Cells were imaged with a scanning confocal microscope. The images shown represent the middle stack slice.